Michael Ferguson
Direktor/Vorstandsmitglied bei NANOVIBRONIX, INC.
Vermögen: - $ am 31.05.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Harold Jacob | M | 69 | 21 Jahre | |
| Ira Greenstein | M | 63 | 10 Jahre | |
| Stephen Brown | M | 67 | 9 Jahre | |
| Brian Murphy | M | 67 | 8 Jahre | |
| Franco Cassar | M | 63 | 2 Jahre | |
| Martin Goldstein | M | 56 | 9 Jahre | |
| Thomas Mika | M | 72 | 9 Jahre | |
| Aurora Cassirer | F | 72 | 2 Jahre | |
| Brian W. Clymer | M | 77 |
Independent College Fund of New Jersey
| - |
| Julien Benitah | M | 41 | 2 Jahre | |
| Rachel Bitan | F | 37 | 2 Jahre | |
| Fashek Christopher | M | 74 | 8 Jahre | |
| Maria Schroeder | F | 65 | 2 Jahre | |
| James Lasry | M | 55 | 2 Jahre | |
| Reid Brockmeier | M | - |
Independent College Fund of New Jersey
| - |
| Jamaleddine Mustapha | M | 62 | 2 Jahre | |
| Mustapha Ghazali | M | 52 | 2 Jahre | |
| Patrick Migliaccio | M | 50 |
Independent College Fund of New Jersey
| - |
| Lindsey Harrison | F | - | 3 Jahre | |
| Itai Levinson | M | - | 6 Jahre | |
| Saâd Bendidi | M | 65 | 2 Jahre | |
| David M. Daly | M | - |
Independent College Fund of New Jersey
| - |
| Douglas G. Swenson | M | - |
Independent College Fund of New Jersey
| - |
| Frank D'Amelio | M | 66 |
Independent College Fund of New Jersey
| - |
| Kevin Cummings | M | 68 |
Independent College Fund of New Jersey
| - |
| Glenn C. Lockwood | M | 62 |
Independent College Fund of New Jersey
| - |
| Oury Marciano | M | 39 | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Samuel Backenroth | M | 39 |
Ohr Pharmaceutical, Inc.
 Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 9 Jahre |
| Jason Scott Slakter | M | 66 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 5 Jahre |
| William Stern | M | 82 | 3 Jahre | |
| Orin Hirschman | M | 54 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 10 Jahre |
| June Almenoff | M | 67 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 6 Jahre |
| Thomas M. Riedhammer | M | 76 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 6 Jahre |
| James Cardwell | M | 64 | 1 Jahre | |
| Jona Zumeris | M | 73 | 15 Jahre | |
| Claude Benitah | M | 74 | 2 Jahre | |
| John M. Horne | M | 56 | - | |
| Amir Rippel | M | - | 10 Jahre | |
| Avner Ingerman | M | 60 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 29 | 74,36% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Michael Ferguson
- Persönliches Netzwerk
